<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2017-10-12 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment." The purpose of this draft guidance is to assist sponsors in all phases of antiviral drug development for prophylaxis and treatment of disease caused by respiratory syncytial virus (RSV) infection.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2017-22051</p>
    <p><strong>Publication Date:</strong> 2017-10-12</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2017/10/12/2017-22051/respiratory-syncytial-virus-infection-developing-antiviral-drugs-for-prophylaxis-and-treatment-draft">https://www.federalregister.gov/documents/2017/10/12/2017-22051/respiratory-syncytial-virus-infection-developing-antiviral-drugs-for-prophylaxis-and-treatment-draft</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2017-22051</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
